Generic Injectables - Global Market Trajectory & Analytics

Global Generic Injectables Market to Reach $152.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Generic Injectables estimated at US$67.7 Billion in the year 2020, is projected to reach a revised size of US$152.5 Billion by 2027, growing at a CAGR of 12.3% over the period 2020-2027. Large Molecule Injectables (Biosimilars), one of the segments analyzed in the report, is projected to record 11.9% CAGR and reach US$48.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Small Molecule Injectables segment is readjusted to a revised 12.5% CAGR for the next 7-year period.



The U.S. Market is Estimated at $18.3 Billion, While China is Forecast to Grow at 16.2% CAGR

The Generic Injectables market in the U.S. is estimated at US$18.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$33.3 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 10.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Select Competitors (Total 41 Featured):

• Baxter International, Inc.
• Biocon Ltd.
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals PLC
• Lupin Ltd.
• Mylan NV
• Novartis AG
• Pfizer, Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.